Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms - 27/09/17
Abstract |
The mechanism of action of empagliflozin in reducing the risk of adverse cardiovascular outcomes vs placebo in patients with type 2 diabetes mellitus and a high risk of cardiovascular disease in the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA-REG OUTCOME) trial is currently unknown. An antiatherosclerotic effect is considered unlikely given the speed of the observed decrease in cardiovascular mortality. Hemodynamic effects, such as reductions in blood pressure and intravascular volume, and involving osmotic diuresis, may provide a more plausible explanation. Metabolic effects, such as cardiac fuel energetics, and hormonal effects, such as increased glucagon release, may also contribute to the results observed during EMPA-REG OUTCOME. This review discusses the main hypotheses suggested to date.
El texto completo de este artículo está disponible en PDF.Keywords : Cardiovascular outcomes, Empagliflozin, Mechanisms, Sodium glucose cotransporter 2 inhibitors
Esquema
| Funding: This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc. Writing support was provided by Debra Brocksmith, MB ChB, PhD, of Envision Scientific Solutions, which was contracted and funded by Boehringer Ingelheim Pharmaceuticals, Inc. The author received no direct or indirect compensation related to the development of the manuscript. |
|
| Conflict of Interest: BS has no conflicts of interest to disclose with respect to this paper. |
|
| Authorship: The author meets criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The author was fully responsible for all content and editorial decisions, was involved at all stages of manuscript development, and approved the final version that reflects the author's interpretation and conclusions. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations. |
|
| This article is co-published in The American Journal of Medicine (Vol. 130, Issue 6S, June 2017) and The American Journal of Cardiology (Vol. 120, Issue 1S, July 1, 2017). |
Vol 130 - N° 6S
P. S30-S39 - juin 2017 Regresar al número
Artículo precedente
- Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes
- Francesco Paneni, Thomas F. Lüscher
- Diabetes Mellitus and Heart Failure
- Michael Lehrke, Nikolaus Marx
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?